Európska únia - slovenčina - EMA (European Medicines Agency)

novartis ireland ltd - ofatumumab - roztrúsená skleróza, recidivujúce-odosielajúcej - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.